^
Association details:
| Biomarker: | SMARCB1 negative |
|---|---|
| Cancer: | Spindle Cell Sarcoma |
| Drug: | Tazverik (tazemetostat) (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort)
Published date:
10/01/2018
Excerpt:
There were a total of 3/32 PRs (2 SCS and 1 SNC)...tazemetostat treatment resulted in long-term clinical activity in 2/13 pts with INI1-negative sarcomas…
DOI:
10.1093/annonc/mdy299.010
Trial ID:
